Mojgan Zarif

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation

Davidson Zhao, Mojgan Zarif, Qianghua Zhou et al. · Cancers · 2023 · 28 citations · Full text

Medicine, Hematology, Oncology +14

NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1

Davidson Zhao, Mojgan Zarif, Entsar Eladl et al. · Leukemia Research · 2022 · 17 citations

Medicine, Genetics, Oncology +10

Molecular characterization of <scp>AML‐MRC</scp> reveals <scp><i>TP53</i></scp> mutation as an adverse prognostic factor irrespective of <scp>MRC</scp>‐defining criteria, <scp><i>TP53</i></scp> allelic state, or <scp><i>TP53</i></scp> variant allele frequency

Davidson Zhao, Entsar Eladl, Mojgan Zarif et al. · Cancer Medicine · 2022 · 17 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria

Qianghua Zhou, Davidson Zhao, Mojgan Zarif et al. · Blood Advances · 2024 · 16 citations · Full text

Medicine, Hematology, Oncology +17